Diabetic Foot Ulcers - Pipeline Review, H1 2017

  • ID: 4284822
  • Report
  • 132 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ANP Technologies Inc
  • CytoTools AG
  • GlaxoSmithKline Plc
  • NovaLead Pharma Pvt Ltd
  • RMB-Research GmbH
  • Theravasc Inc
  • MORE
Diabetic Foot Ulcers - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2017, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 12, 6, 22, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ANP Technologies Inc
  • CytoTools AG
  • GlaxoSmithKline Plc
  • NovaLead Pharma Pvt Ltd
  • RMB-Research GmbH
  • Theravasc Inc
  • MORE
Introduction

Diabetic Foot Ulcers - Overview

Diabetic Foot Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Foot Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development

ANP Technologies Inc

Anterogen Co Ltd

Boston Therapeutics Inc

CardioVascular BioTherapeutics Inc

Celgene Corp

Chrysalis BioTherapeutics Inc

CytoTools AG

EyeGene Inc

FirstString Research Inc

Genentech Inc

GlaxoSmithKline Plc

Human Stem Cells Institute

Izun Pharmaceuticals Corp

Lakewood-Amedex Inc

MediWound Ltd

NovaLead Pharma Pvt Ltd

Oneness Biotech Co Ltd

Osiris Therapeutics Inc

Pherecydes Pharma SA

RMB-Research GmbH

Serodus ASA

Stempeutics Research Pvt Ltd

Stratatech Corp

TechnoPhage SA

Theravasc Inc

Topadur Pharma AG

USV Pvt Ltd

viDA Therapeutics Inc

ViroMed Co Ltd

Diabetic Foot Ulcers - Drug Profiles

3K3A-APC - Drug Profile

ALLO-ASC - Drug Profile

ANP-017 - Drug Profile

AP-185 - Drug Profile

APO-2 - Drug Profile

AUP-16 - Drug Profile

becaplermin biosimilar - Drug Profile

Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile

Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile

CODA-001 - Drug Profile

CVBT-141B - Drug Profile

Cyndacel-M - Drug Profile

daprodustat - Drug Profile

diperoxochloric acid - Drug Profile

EG-Decorin - Drug Profile

epidermal growth factor biosimilar - Drug Profile

EscharEx - Drug Profile

esmolol hydrochloride - Drug Profile

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile

Granexin - Drug Profile

Heberprot-P - Drug Profile

IMSP-001 - Drug Profile

Ipoxyn - Drug Profile

IZN-6D4 - Drug Profile

MT-003 - Drug Profile

NAS-911 - Drug Profile

Neovasculgen - Drug Profile

Nu-2 - Drug Profile

Nu-3 - Drug Profile

ON-101 - Drug Profile

OTI-1501 - Drug Profile

PDA-002 - Drug Profile

PP-2351 - Drug Profile

Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile

RG-7880 - Drug Profile

rusalatide acetate - Drug Profile

SER-190 - Drug Profile

sodium nitrite SR - Drug Profile

Statmicoll - Drug Profile

Stempeucel - Drug Profile

TOPN-53 - Drug Profile

TP-102 - Drug Profile

V-10 - Drug Profile

V-2248 - Drug Profile

VM-202 - Drug Profile

VTI-1000 Series - Drug Profile

VTI-3000 Series - Drug Profile

Diabetic Foot Ulcers - Dormant Projects

Diabetic Foot Ulcers - Discontinued Products

Diabetic Foot Ulcers - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Diabetic Foot Ulcers, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H1

Diabetic Foot Ulcers - Pipeline by Anterogen Co Ltd, H1

Diabetic Foot Ulcers - Pipeline by Boston Therapeutics Inc, H1

Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H1

Diabetic Foot Ulcers - Pipeline by Celgene Corp, H1

Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H1

Diabetic Foot Ulcers - Pipeline by CytoTools AG, H1

Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H1

Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H1

Diabetic Foot Ulcers - Pipeline by Genentech Inc, H1

Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H1

Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H1

Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H1

Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H1

Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H1

Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1

Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H1

Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H1

Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H1

Diabetic Foot Ulcers - Pipeline by RMB-Research GmbH, H1

Diabetic Foot Ulcers - Pipeline by Serodus ASA, H1

Diabetic Foot Ulcers - Pipeline by Stempeutics Research Pvt Ltd, H1

Diabetic Foot Ulcers - Pipeline by Stratatech Corp, H1

Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H1

Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H1

Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H1

Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H1

Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H1

Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H1

Diabetic Foot Ulcers - Dormant Projects, H1

Diabetic Foot Ulcers - Dormant Projects, H1 2017 (Contd..1), H1

Diabetic Foot Ulcers - Dormant Projects, H1 2017 (Contd..2), H1

Diabetic Foot Ulcers - Discontinued Products, H1

List of Figures:

Number of Products under Development for Diabetic Foot Ulcers, H1

Number of Products under Development by Companies, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ANP Technologies Inc
  • Anterogen Co Ltd
  • Boston Therapeutics Inc
  • CardioVascular BioTherapeutics Inc
  • Celgene Corp
  • Chrysalis BioTherapeutics Inc
  • CytoTools AG
  • EyeGene Inc
  • FirstString Research Inc
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Human Stem Cells Institute
  • Izun Pharmaceuticals Corp
  • Lakewood-Amedex Inc
  • MediWound Ltd
  • NovaLead Pharma Pvt Ltd
  • Oneness Biotech Co Ltd
  • Osiris Therapeutics Inc
  • Pherecydes Pharma SA
  • RMB-Research GmbH
  • Serodus ASA
  • Stempeutics Research Pvt Ltd
  • Stratatech Corp
  • TechnoPhage SA
  • Theravasc Inc
  • Topadur Pharma AG
  • USV Pvt Ltd
  • viDA Therapeutics Inc
  • ViroMed Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll